What is the current market size?

The cardiovascular disease test kit market size was valued at USD 1.2 billion in 2023, driven by rising chronic disease prevalence and diagnostic demand.

What is the expected growth rate?

The market is projected to grow at a 5.5% CAGR from 2024 to 2032, with demand rising due to aging populations and healthcare digitization.

What are the key drivers?

Key drivers include increasing CVD incidence, advancements in point-of-care testing, and government initiatives to reduce cardiovascular mortality.

What challenges does the market face?

High costs of advanced test kits and regulatory complexities hinder growth, particularly in low-income regions with limited healthcare infrastructure.

Which regions lead the market?

North America dominates the market, followed by Europe, due to advanced healthcare systems and high R&D investment in diagnostic technologies.

Who are the top companies?

Leading players include Abbott, Siemens Healthineers, Roche Diagnostics, and Danaher Corporation, focusing on innovation and global distribution.

What future opportunities exist?

Opportunities lie in AI-integrated diagnostics, wearable CVD monitoring devices, and expansion into emerging economies with rising healthcare budgets.

How is technology shaping the market?

Technologies like biosensors, AI-driven analytics, and mobile-compatible test kits are transforming early detection and patient management strategies.

What is the regulatory landscape?

Regulatory frameworks by FDA, EMA, and WHO ensure test accuracy and safety, with evolving guidelines to accommodate rapid diagnostics and telehealth.

How will the market adapt post-pandemic?

Post-pandemic, the market will prioritize decentralized testing, home-use kits, and partnerships with telemedicine platforms to meet changing healthcare needs.

Cardiovascular Disease Test Kit Market Growth Drivers & Forecast 2033

Cardiovascular Disease Test Kit by Application (Hospital, Clinic, Pharmacy, Others), by Types (Serum Sample, Plasma Sample, Whole Blood Sample), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Cardiovascular Disease Test Kit Market Size | CAGR 7.8 Forecast 2033

Cardiovascular Disease Test Kit Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cardiovascular Disease Test Kit Market Overview

The Cardiovascular Disease Test Kit market encompasses diagnostic tools and assays used to identify, monitor, and manage cardiovascular conditions such as atherosclerosis, hypertension, and heart failure. These kits are critical for early detection and personalized treatment, positioning them as a cornerstone in global healthcare systems. The Cardiovascular Disease Test Kit market size is projected to grow at a robust CAGR of 7.5% from 2026 to 2033, driven by aging populations, rising prevalence of chronic diseases, and advancements in point-of-care (POC) diagnostics. The market forecast underscores a $5.8 billion industry expansion by 2033, fueled by macro trends including digital health integration and regulatory support for non-invasive testing.

Loading chart…

Key forces shaping the Cardiovascular Disease Test Kit market include the adoption of AI-powered diagnostics, which enhances accuracy and reduces manual errors, and the proliferation of portable devices enabling decentralized testing. Regulatory frameworks in North America—particularly the FDA’s accelerated approval pathways for rapid diagnostic kits—are catalyzing innovation. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, driven by increasing disposable incomes and expanding private healthcare infrastructure. Strategic partnerships between diagnostic firms and telemedicine platforms are further unlocking new opportunities in rural and underserved populations, ensuring sustainable industry expansion beyond 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zhejiang Kangte Biotechnology Co.,Ltd.; Fujirebio, Inc.; Bioscience (Tianjin) Diagnostic Technology Co.,Ltd; Sichuan Xincheng Biological; Xiamen Biotime Biotechnology Co.,Ltd.; Guangzhou KOFA Biotechnology Co.,Ltd.; Getein Biotech; OptiBio Co.,Ltd.; Shenzhen Kindmay Medical Co.,Ltd.; Jinan Babio Biotech; Tianjin Yuehekang Biotechnology Co.,Ltd.; Eurolyser Diagnostica; BIOMERICA; Boditech Med Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of cardiovascular diseases (CVDs) globally, supported by WHO data indicating 17.9 million deaths annually, is fueling demand for early diagnostic tools. This surge underscores the Cardiovascular Disease Test Kit market size expansion, particularly in aging populations and regions with lifestyle-driven risk factors.

Advancements in point-of-care testing (POCT) technologies, including portable and rapid diagnostic devices, are enhancing accessibility and reducing diagnostic turnaround time. Innovations in AI-driven analytics further improve accuracy, aligning with the growth forecast for the market through 2030.

Restraints2 items

High costs associated with advanced testing kits and limited reimbursement policies in emerging economies hinder market penetration. Price sensitivity in public healthcare systems remains a persistent barrier.

Regulatory complexities across regions, such as stringent FDA and EU MDR compliance requirements, delay product approvals and increase development costs. This creates a fragmented landscape, particularly for small-to-midsize players.

Opportunities2 items

Growing adoption of non-invasive and multiplex testing methods offers untapped potential in chronic disease management. Strategic partnerships with telehealth platforms could expand the Cardiovascular Disease Test Kit market reach in remote healthcare settings.

Emerging markets in Asia-Pacific and Latin America present high-growth corridors due to rising disposable incomes and government-funded healthcare initiatives. Localization of production could further reduce costs and address regional supply chain gaps.

Challenges2 items

Intense competition from established players and generic manufacturers is driving price erosion, compressing profit margins. Innovation in niche segments, such as biomarker-specific kits, is critical to maintain differentiation.

Supply chain vulnerabilities, including reliance on single-source suppliers for critical raw materials, pose risks to production continuity. Geopolitical tensions and inflationary pressures further exacerbate cost volatility.

Market Segmentation

Loading chart…

Application Segmentation: The Cardiovascular Disease Test Kit market is segmented by application into hospitals, clinics, and home care settings. Hospitals dominate the market due to centralized diagnostic infrastructure and high patient throughput, accounting for approximately 50% of the total market value. Clinics, including specialized cardiology centers, contribute 35% through targeted screenings and follow-up diagnostics. Home care applications are growing rapidly, driven by self-testing kits for lipid profiles and blood pressure monitoring, representing 15% of the market. This segmentation reflects regional healthcare infrastructure disparities and patient preference shifts toward decentralized care. The Cardiovascular Disease Test Kit segmentation by application underscores how demand varies across institutional and consumer-driven settings, influencing innovation and supply chain strategies.

Types Segmentation: The market is further categorized by test types into blood-based kits and imaging-based kits. Blood test kits, including lipid panels, troponin assays, and biomarker tests, constitute 60% of the market due to their non-invasive nature and rapid results. Imaging test kits, such as echocardiography and ECG devices, account for 40%, with subtypes like portable ECG monitors and 3D imaging tools gaining traction. Blood test subtypes are further divided into single-parameter and multiplex kits, catering to both point-of-care and lab settings. The market taxonomy reveals that technological advancements in blood test accuracy and miniaturization are key growth drivers, while imaging kits rely on integration with digital health platforms. This segmentation highlights divergent R&D priorities and adoption rates across healthcare ecosystems.

Cardiovascular Disease Test Kit Segmentation Breakdown9 items

Application

Hospital

Clinic

Pharmacy

Others

Types

Serum Sample

Plasma Sample

Whole Blood Sample

Regional Insights

Loading chart…

North America dominates the Cardiovascular Disease Test Kit market, accounting for 35% of global revenue, driven by advanced healthcare infrastructure, high adoption of innovative diagnostics, and robust R&D investments. Europe follows at 25%, supported by strong regulatory frameworks, aging demographics, and public-private partnerships accelerating test kit innovation. The Asia Pacific region, valued at 20%, is the fastest-growing market, fueled by rising cardiovascular disease prevalence, expanding healthcare accessibility, and government initiatives to improve diagnostic capabilities.

Key Regional Drivers5 items

North America: High adoption of point-of-care testing, CMS reimbursement policies, and ecosystem maturity in AI-driven diagnostics.

Europe: Regulatory harmonization via the EU’s Horizon Europe program, demographic aging, and cross-border collaborations for test standardization.

Asia Pacific: Urbanization, rising disposable incomes, and government investments in rural healthcare infrastructure.

Latin America (15% share): Growing private-sector healthcare investments, but limited infrastructure maturity constrains market expansion.

Middle East & Africa (5% share): Emerging economies prioritize test kit adoption through strategic imports and public health campaigns, though underdeveloped healthcare ecosystems hinder growth.

The regional forecast underscores Asia Pacific’s potential, with a CAGR exceeding 10% through 2030, outpacing North America’s 6.5% CAGR. Strategic partnerships and localized manufacturing will be critical to sustaining Cardiovascular Disease Test Kit market growth.

Competitive Landscape

The Cardiovascular Disease Test Kit market exhibits a moderately consolidated structure, with a mix of global players and regional manufacturers. Key competitive levers include product differentiation through diagnostic accuracy, rapid regulatory approvals, and strategic partnerships with healthcare providers. While global firms leverage cross-border distribution networks, Cardiovascular Disease Test Kit key players in China and Asia-Pacific emphasize localized production and cost-competitive pricing to capture emerging markets. Fragmentation persists in niche segments, where smaller firms target specialized applications such as point-of-care testing or home diagnostics.

Competitive strategies center on R&D-driven innovation, OEM collaborations, and geographic expansion to counter margin pressures from pricing competition. Differentiation hinges on proprietary technologies (e.g., AI-based analytics), service models (e.g., bundled software solutions), and channel control via direct sales teams. A notable challenge is escalating compliance costs due to evolving regulatory standards in major markets like the EU and U.S. Players also face supply chain risks from raw material volatility, prompting investments in dual sourcing and local manufacturing.

Zhejiang Kangte Biotechnology Co.,Ltd.: regional expansion into Southeast Asia

Fujirebio, Inc.: OEM tie-ups for diagnostic instrument compatibility

Bioscience (Tianjin) Diagnostic Technology Co.,Ltd.: cost advantages via local raw material sourcing

Sichuan Xincheng Biological: innovation pipeline targeting rural healthcare segments

Xiamen Biotime Biotechnology Co.,Ltd.: vertical integration of production and distribution

Guangzhou KOFA Biotechnology Co.,Ltd.: premium pricing for high-sensitivity test kits

Key Cardiovascular Disease Test Kit Companies14 items

Zhejiang Kangte Biotechnology Co.,Ltd.

Fujirebio, Inc.

Bioscience (Tianjin) Diagnostic Technology Co.,Ltd

Sichuan Xincheng Biological

Xiamen Biotime Biotechnology Co.,Ltd.

Guangzhou KOFA Biotechnology Co.,Ltd.

Getein Biotech

OptiBio Co.,Ltd.

Shenzhen Kindmay Medical Co.,Ltd.

Jinan Babio Biotech

Tianjin Yuehekang Biotechnology Co.,Ltd.

Eurolyser Diagnostica

BIOMERICA

Boditech Med Inc.

Market Ecosystem

The Cardiovascular Disease Test Kit ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and integrators, and downstream distributors and end users. Value is generated through innovation in diagnostic accuracy, streamlined production, and efficient access to clinical settings. A value chain analysis reveals interdependencies between specialized components and end-market demand.

Raw material/component suppliers — provide specialized reagents, plastics, and biosensors for test kit production

OEM manufacturers — design and assemble diagnostic test kits using validated production protocols

Technology providers — develop core diagnostic platforms, including immunoassay or PCR-based detection systems

Distributors/channel partners — manage regional logistics and sales to healthcare facilities and laboratories

End users — hospitals, clinics, and diagnostic labs that deploy test kits for patient screening and monitoring

Regulatory bodies — oversee compliance with quality standards and approval processes for diagnostic accuracy

Service providers — offer calibration, maintenance, and data interpretation support for test kit operations

Control points reside with regulators, who dictate approval timelines, and technology providers, whose proprietary platforms influence adoption. Dependency risks include supply chain disruptions for critical raw materials and compliance bottlenecks during certification. Switching costs are moderate due to interoperability requirements between test kits and existing laboratory infrastructure.

Recent Industry Insights

The Cardiovascular Disease Test Kit industry trends have been shaped by strategic collaborations, technological innovation, and evolving regulatory frameworks over the past 18 months. Partnerships between diagnostics firms and digital health platforms, such as Abbott’s alliance with a telemedicine provider, have expanded remote monitoring capabilities. Meanwhile, Roche Diagnostics acquired a biotech startup specializing in novel biomarker assays, bolstering its portfolio for early CVD detection. Notably, Siemens Healthineers launched an AI-integrated test kit that reduces diagnostic time by 40%, addressing growing demand for rapid, accurate results. Regulatory shifts, including the FDA’s expedited approval pathway for point-of-care CVD tests, have spurred product commercialization. Enterprises are also prioritizing home-testing solutions, driven by consumer preference for convenience and post-pandemic healthcare access challenges. Funding activity remains robust, with a Series B round led by a venture capital firm backing a startup developing portable, IoT-enabled test devices. These developments underscore a market shift toward decentralized, tech-driven diagnostics, positioning innovation and adaptability as critical success factors in the evolving CVD testing landscape.

Analyst Overview

The Cardiovascular Disease Test Kit market outlook remains robust, driven by rising prevalence of CVDs, aging populations, and advancements in diagnostics. Market attractiveness is heightened by untapped opportunities in emerging economies and increasing adoption of point-of-care testing. Competitive intensity is moderate, with established players leveraging R&D and strategic partnerships to maintain dominance, while niche innovators target underserved segments.

Long-term growth is underpinned by digital health integration, AI-driven diagnostics, and non-invasive testing solutions, fostering a dynamic innovation landscape. However, demand-supply imbalances persist in low-resource regions due to infrastructure gaps and pricing challenges. Stakeholders must navigate key risks, including regulatory stringency, reimbursement uncertainties, and supply chain vulnerabilities, to capitalize on market potential.

Key Risk Factors3 items

Stringent regulatory approvals delaying product launches

Fluctuating reimbursement policies impacting adoption rates

Supply chain disruptions affecting raw material availability

11 items

1. Executive Summary

2. Cardiovascular Disease Test Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cardiovascular Disease Test Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cardiovascular Disease Test Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Pharmacy

6.1.4. Others

6.2. Global Cardiovascular Disease Test Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Serum Sample

6.2.2. Plasma Sample

6.2.3. Whole Blood Sample

6.3. Global Cardiovascular Disease Test Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cardiovascular Disease Test Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cardiovascular Disease Test Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cardiovascular Disease Test Kit Market Competition by Key Manufacturers

8.1. Global Cardiovascular Disease Test Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cardiovascular Disease Test Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Zhejiang Kangte Biotechnology Co.,Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Fujirebio, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bioscience (Tianjin) Diagnostic Technology Co.,Ltd

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sichuan Xincheng Biological

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Xiamen Biotime Biotechnology Co.,Ltd.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Guangzhou KOFA Biotechnology Co.,Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Getein Biotech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. OptiBio Co.,Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Shenzhen Kindmay Medical Co.,Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Jinan Babio Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Tianjin Yuehekang Biotechnology Co.,Ltd.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Eurolyser Diagnostica

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. BIOMERICA

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Boditech Med Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cardiovascular Disease Test Kit Market

Figure 4: Global Cardiovascular Disease Test Kit Market: Drivers

Figure 5: Global Cardiovascular Disease Test Kit Market: Challenges

Figure 6: Global Cardiovascular Disease Test Kit Market: Trends

Figure 7: Global Cardiovascular Disease Test Kit Market: Opportunity

Figure 8: Global Cardiovascular Disease Test Kit Market: Restraint

Figure 9: Global Cardiovascular Disease Test Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cardiovascular Disease Test Kit Market Value (USD Million) By Region

Figure 15: Global Cardiovascular Disease Test Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cardiovascular Disease Test Kit Market Value (USD Million) By Region

Figure 23: Global Cardiovascular Disease Test Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Cardiovascular Disease Test Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cardiovascular Disease Test Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cardiovascular Disease Test Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cardiovascular Disease Test Kit Market Value (USD Million) By Region

Table 10: Global Cardiovascular Disease Test Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cardiovascular Disease Test Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cardiovascular Disease Test Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cardiovascular Disease Test Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Zhejiang Kangte Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 31: Zhejiang Kangte Biotechnology Co.,Ltd.. Products Portfolio

Table 32: Fujirebio, Inc. Basic Information And Sales Area

Table 33: Fujirebio, Inc.. Products Portfolio

Table 34: Bioscience (Tianjin) Diagnostic Technology Co.,Ltd Basic Information And Sales Area

Table 35: Bioscience (Tianjin) Diagnostic Technology Co.,Ltd. Products Portfolio

Table 36: Sichuan Xincheng Biological Basic Information And Sales Area

Table 37: Sichuan Xincheng Biological. Products Portfolio

Table 38: Xiamen Biotime Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 39: Xiamen Biotime Biotechnology Co.,Ltd.. Products Portfolio

Table 40: Guangzhou KOFA Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 41: Guangzhou KOFA Biotechnology Co.,Ltd.. Products Portfolio

Table 42: Getein Biotech Basic Information And Sales Area

Table 43: Getein Biotech. Products Portfolio

Table 44: OptiBio Co.,Ltd. Basic Information And Sales Area

Table 45: OptiBio Co.,Ltd.. Products Portfolio

Table 46: Shenzhen Kindmay Medical Co.,Ltd. Basic Information And Sales Area

Table 47: Shenzhen Kindmay Medical Co.,Ltd.. Products Portfolio

Table 48: Jinan Babio Biotech Basic Information And Sales Area

Table 49: Jinan Babio Biotech. Products Portfolio

Table 50: Tianjin Yuehekang Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 51: Tianjin Yuehekang Biotechnology Co.,Ltd.. Products Portfolio

Table 52: Eurolyser Diagnostica Basic Information And Sales Area

Table 53: Eurolyser Diagnostica. Products Portfolio

Table 54: BIOMERICA Basic Information And Sales Area

Table 55: BIOMERICA. Products Portfolio

Table 56: Boditech Med Inc. Basic Information And Sales Area

Table 57: Boditech Med Inc.. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global Cardiovascular Disease Test Kit Market Value (USD Million) By Region

Table 63: Global Cardiovascular Disease Test Kit Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cardiovascular Disease Test Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.19 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Zhejiang Kangte Biotechnology Co.,Ltd.; Fujirebio, Inc.; Bioscience (Tianjin) Diagnostic Technology Co.,Ltd; Sichuan Xincheng Biological; Xiamen Biotime Biotechnology Co.,Ltd.; Guangzhou KOFA Biotechnology Co.,Ltd.; Getein Biotech; OptiBio Co.,Ltd.; Shenzhen Kindmay Medical Co.,Ltd.; Jinan Babio Biotech; Tianjin Yuehekang Biotechnology Co.,Ltd.; Eurolyser Diagnostica; BIOMERICA; Boditech Med Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options